Skip to content
Research Article Open access CC BY 3.0

Serum and Urine Electrolyte Profiles during Amlodipine and Hydrochlorothiazide Combination Therapy in Nigerian Patients with Essential Hypertension

Godfrey B. S. Iyalomhe, Eric K. I. Omogbai, Osigbemhe O. B. Iyalomhe, Sarah I. Iyalomhe

Journal of Advances in Medicine and Medical Research · pp. 428–441 · Published 19 Feb 2013

10.9734/BJMMR/2013/2485

Abstract

Aims: To evaluate changes in electrolyte profiles during combination treatment with amlodipine (AML) and hydrochlorothiazide (HCZ) in hypertensive Nigerians. Study Design: Randomized, open-label, prospective, two-centre, outpatient, 48-week study. Methodology: We enrolled 90 male and female Nigerians aged 31-86 years with uncomplicated essential hypertension (blood pressure [BP] > 160/90 ≤ 180/120mmHg). Patients, who were 30 each (15males [M] and 15females [F]) in AML, HCZ and AML-HCZ groups, were treated, respectively, with 5mg AML for 6 weeks (wks) and the dose increased to 10mg till wk 12 (monotherapy) after which HCZ 25mg was added; HCZ 25mg till wk 6 (monotherapy) after which AML 5-10mg was added; and AML 5-10mg + HCZ 25mg. Body mass index (BMI), BP, 24h urine volume, serum and urine electrolytes (Na+, K+, Cl-) were assessed at baseline and at the end of wks 1, 3, 6, 12, 24, 36 and 48 during treatment. Results: The 3 regimens comparably significantly (P= .05) reduced BP. Diuresis was greatest and significant (P= .05) in HCZ group. A time dependent significant (P< .0001) hyponatraemic changes were observed in all subgroups except AML M subgroup such that the mean maximum M/F decrease in AML, HCZ and AML-HCZ groups, respectively, were 5.07/14.74, 17.40/16.40 and 10.93/16.86 mmol/L. A parallel significant (P< .01) increase in urine Na+ was observed in all groups with maximum mean M/F increase in AML, HCZ and AML-HCZ groups being, respectively, 26.00/24.40, 28.07/40.94 and 30.47/27.67 mmol/L. A baseline hypokalaemia was observed in all groups except in the AML M subgroup. Significant (P< .0001) M/F hypokalaemic changes were 0.23/0.35, 0.76/0.53 and 0.18/0.19 mmol/L for AML, HCZ and AML-HCZ groups, respectively. Corresponding significant (P< .0001) M/F increase in urine K+ were 4.60/5.71, 10.67/18.60 and 8.2/9.3 mmol/L for AML, HCZ and AML-HCZ groups, respectively. Significant (P= .05) disproportionate chloraemia was observed at baseline in all groups. The observed significant (P< .0001) M/F hypochloraemic changes in AML, HCZ and AML-HCZ groups were, respectively, 10.60/11.46, 25.60/26.94 and 22.93/17.67. A significant (P < .0001) parallel hyperchloriuria was evident in all groups and M/F values in AML, HCZ and AML-HCZ groups were, respectively, 8.09/6.46, 26.00/39.86 and 24.53/18.00 mmol/L. Conclusion: Long-term AML and HCZ combination therapy, though effective, is associated with biochemical changes – Na+, K+ and Cl- depletion, thus making serum electrolytes monitoring and K+ supplementation or concomitant use of a K+-sparing diuretic clinically imperative.

Serum and urine electrolytes amlodipine and hydrochlorothiazide antihypertensive combination therapy Nigerians essential hypertension

References (27)

  1. 1 Global burden of hypertension: analysis of worldwide data [DOI]
  2. 2 Recommendations for Blood Pressure Measurement in Humans and Experimental Animals [DOI]
  3. 3 Hypertension Treatment and Control in Five European Countries, Canada, and the United States [DOI]
  4. 4 Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document [DOI]
  5. 5 G12-G13–LARG–mediated signaling in vascular smooth muscle is required for salt-induced hypertension [DOI]
  6. 6 Hypertension-related knowledge, attitudes and life-style practices among hypertensive patients in a sub-urban Nigerian community [DOI]
  7. 7 Moderate salt restriction effectively lowers blood pressure and degree of salt sensitivity is related to baseline concentration of renin and N-terminal atrial natriuretic peptide in plasma [DOI]
  8. 8 Mechanisms of Disease: WNK-ing at the mechanism of salt-sensitive hypertension [DOI]
  9. 9 Current Epidemiology of Hypertension in Nigeria [DOI]
  10. 10 Effects of Monotherapy and Combination Therapy on Blood Pressure Control and Target Organ Damage: A Randomized Prospective Intervention Study in a Large Population of Hypertensive Patients [DOI]
  11. 11 Prevalence of hypertension and its complications among medical admissions at the University of Nigeria Teaching Hospital, Enugu (Study 2).
  12. 12 Modest Salt Reduction Lowers Blood Pressure in Isolated Systolic Hypertension and Combined Hypertension [DOI]
  13. 13 Evolving strategies for the use of combination therapy in hypertension [DOI]
  14. 14 Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management [DOI]
  15. 15 Demographic, Environmental, and Genetic Predictors of Metabolic Side Effects of Hydrochlorothiazide Treatment in Hypertensive Subjects [DOI]
  16. 16 Effect of Antihypertensive Therapy on Serum Lipids in Newly Diagnosed Essential Hypertensive Men [DOI]
  17. 17 Combination therapy with renin-angiotensin system blockers: Will amlodipine replace hydrochlorothiazide? [DOI]
  18. 18 Antihypertensive and Some Biochemical Effects of Hydrochlorothiazide and Furosemide in Some Nigerians [DOI]
  19. 19 Ethnic aspects of hypertension [DOI]
  20. 20 Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update [DOI]
  21. 21 Electrolyte profiles in Nigerian patients with essential hypertension [DOI]
  22. 22 Enalapril and hydrochlorothiazide in hypertensive Africans [DOI]
  23. 23 Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy [DOI]
  24. 24 Open evaluation of amlodipine in the monotherapeutic treatment of mild to moderate hypertension in nigerian patients [DOI]
  25. 25 Effects of hydrochlorothiazide and furosemide on creatinine clearance in some hypertensive Nigerians [DOI]
  26. 26 A comparison of moduretic and hydrochlorothiazide in the treatment of hypertension in African patients.
  27. 27 Risk/Benefit Assessment of β-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension [DOI]

Cited by 2

Clinical Adverse Events Profile during Combination Therapy with Amlodipine and Hydrochlorothiazide in Hypertensive Nigerians

G. B. S. Iyalomhe, E. K. I. Omogbai, A. Isah · 2014

The Increasing Burden of Uncontrolled Hypertension in Nigeria: The Role of Lifestyle Modification Practices as an Effective Strategy to Reverse the Trend.

Iyalomhe Gbs, Iyalomhe Si · 2015

Related research

Article metrics

Real usage data collected on this platform.

41

Page views

0

PDF downloads

11

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.